Kymera Therapeutics Presents Data Demonstrating Superior Efficacy of KT-253, a Potent and Selective Heterobifunctional MDM2 Degrader, Compared to Small Molecule Inhibitor in Preclinical Leukemia Models at the European Hematology Association Congress
A single dose of KT-253 drives tumor regression and demonstrates differentiated pharmacology compared to small molecule inhibitor in preclinical models of ALL and AMLWATERTOWN, Mass., June 09, 2023 ... | June 9, 2023
Source: marketscreener.com